InterMune Inc: Premium Company Profile

Publication Date	December 2007
Publisher	Datamonitor
Product Type	Databook
Pages	50
ISBN Number	not applicable
Product Code	DAT09427

Price

£265.00
approximately: $521 | €337

PRINT £265 ($521 | €337)

Order above formats by FAX

Summary

Introduction

InterMune is a biopharmaceutical company focused on developing and commercializing innovative therapies in hepatology and pulmonology. The company markets Actimmune (interferon gamma-1b), approved for the treatment of severe, malignant osteopetrosis and chronic granulomatous disease. The company acquired core patents for pirfenidone from Marnac and KDL in November 2007.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

InterMune has a late-stage and preclinical development pipeline in the areas of pulmonology and hepatology. In pulmonology, the company is developing two therapies for the treatment of idiopathic pulmonary fibrosis (IPF): interferon gamma-1b and pirfenidone and in hepatology, it is expanding options for patients suffering from HCV infections

Historically, the company derived majority of its revenues during 2002-2006 from product sales of Actimmune, Infergen, Amphotec and Oritavancin. The company's total revenues decreased at a CAGR of -5% during 2002-2006, from $112 million to $91 million, representing an absolute decline of -$21 million for the same period.

InterMune's biggest contributor to sales growth out to 2010 will be revenues from Pirfenidone sales. Revenues from Pirfenidone are expected to contribute $111 million in 2010, representing an absolute growth of +$111 million for the period 2006-2010.

Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company's adjusted five year financial data along with key ratios and market capitalization

Content

Overview
Catalyst
- Summary
- Company Structure
- Company Overview and Key Facts
- Business Description
- History
- Company Financials
- Stock Market Performance
- P&L
- Balance Sheet
- Cash Flow
- Business Segment Performance
- Geographic Segment Performance
- Products & Services
- Marketed Products
- Pipeline Products
- Historical Product Sales
- AC Forecast Product Sales
- Competitors and Strategic Business Relationships
- Top Competitors
- Key Suppliers
- Key Clients
- Shareholding Structure
- Strategy
- Company View
- Corporate Strategy
- SWOT Analysis
- Overview
- Strengths
- Weaknesses
- Opportunities
- Threats
- Value Chain Analysis
- Discovery and Product Development
- Scorecard
- Overview
- Scorecard Analysis
- Key Employees
- List of Key Employees
- Key Employee Biographies
- Financial and Operational Overview
- Financial and Operational Overview
Appendix
- Ask the analyst
- Datamonitor consulting
- Disclaimer
- Figure 1: InterMune - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Figure 2: InterMune - Key Strategic Revenues, 2002-2006 ($ Mn)
- Figure 3: InterMune - Key Strategic Revenues, 2006-2010 ($ Mn)
- Table 1: InterMune - Key Facts
- Table 2: InterMune - Year-End Share Price and Market Capitalization, 2002-2006 ($)
- Table 3: InterMune - Key Events Impacting Share Price Performance
- Table 4: InterMune - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table 5: InterMune - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
- Table 6: InterMune - Balance Sheet, 2002-2006 ($ Mn)
- Table 7: InterMune - Cash Flow, 2002-2006 ($ Mn)
- Table 8: InterMune - Revenue Breakdown, 2002-2006 ($ Mn)
- Table 9: InterMune - Geographic Breakdown, 2002-2006 ($ Mn)
- Table 10: InterMune - Marketed Products
- Table 11: InterMune - in-house Pipeline Products
- Table 12: InterMune - Collaboration Pipeline Products
- Table 13: InterMune - Historical Product Sales, 2002-2006 ($ Mn)
- Table 14: InterMune - Forecast Sales, 2006-2010 ($ Mn)
- Table 15: InterMune - Top Competitors
- Table 16: InterMune - Key Suppliers
- Table 17: InterMune - Key Clients
- Table 18: InterMune - Key Shareholders
- Table 19: InterMune - SWOT Analysis Summary
- Table 20: InterMune - Value Chain Analysis
- Table 21: InterMune - Scorecard
- Table 22: InterMune - Key Employees
- Table 23: InterMune - Financial and Operational Overview